List view / Grid view
The EMA has said that patients should continue to use angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), despite reports that these worsen COVID-19 infections.
According to an outlet, the in-house manufacturing of biopharma products has been threatened by the COVID-19 outbreak, especially in China.
A Phase II/III trial to study Kevzara (sarilumab) as a method to reduce the inflammatory response in the lungs of COVID-19 patients has begun outside of the US.
The US FDA has granted approval to BMS for Zeposia, a once daily oral medication for the treatment of relapsing forms of multiple sclerosis.
A summary of the CHMP meeting conclusions, including medicines recommended for approval and indication extension and several safety review findings.
A study conducted in the US has revealed that the majority of medical marijuana dispensed in the US has THC levels of up to 15 percent.
The UK government has reached out to the life sciences sector to ask potential suppliers of COVID-19 testing kits to get in contact.
Mylan and Upjohn (a Pfizer company) revealed they have delayed the transaction due to meeting restrictions and concerns over staff health and safety during the COVID-19 pandemic.
The International Federation of Pharmaceutical Manufacturers and Associations has announced that the biopharma industry has responding swiftly to the COVID-19 pandemic and will further increase its efforts.
The survey indicates that almost all respondents were concerned about the COVID-19 pandemic’s effects on company performance, including supply and demand failures.
A private-public consortium to develop pre-filled syringe packaging has been backed by Jefferies, including a seed capital commitment of at least $10 million.
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
India has stopped exporting the malaria drug Ipca (hydroxychloroquine), despite the FDA lifting its ban on imports due to its potential as a coronavirus treatment.
Gilead Sciences say they are confident they can maintain an expedited regulatory review timeline for remdesivir as a treatment for COVID-19 without Orphan Drug Designation (ODD).
Positive topline results have been announced from a Phase II trial of VENCLEXTA® (venetoclax) in combination with azacitidine in patients with acute myeloid leukaemia (AML).
